A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder

Human Psychopharmacology

Volumn 25, Issue 6, 2010, Pages 509-513

  Soltani, Farhad ^a   Sayyah, Mehdi ^a   Feizy, Fariba ^a   Malayeri, Alireza ^a   Siahpoosh, Amir ^a   Motlagh, Ismail ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Clinical trial; Obsessive compulsive disorder; Ondansetron

Indexed keywords

FLUOXETINE; ONDANSETRON; OXAZEPAM; PLACEBO;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INCREASED APPETITE; INSOMNIA; MALE; OBSESSIVE COMPULSIVE DISORDER; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SIDE EFFECT; STOMACH PAIN; SWEATING; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR;

ADULT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; INTERVIEW, PSYCHOLOGICAL; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; ONDANSETRON; OUTPATIENTS; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 77956577506     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1145     Document Type: Article

References (25)

1. American Psychiatric Association. 2000. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). American Psychiatric Press: Washington, DC.
2. Chen J, Li Z, Pan H, et al. 2001. Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high affinity serotonin transporter: abnormal intestinal motility and the expression of cation transporters. J Neurosci 21: 6348-6361.
3. Eisenberg J, Asnis G. 1986. Lithium as an adjuvant treatment of obsessivecompulsive disorder. Am J Psychiatry 142: 663.
4. Fabi A, Ciccarese M, Metro G, et al. 2008. Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study. Support Care Cancer J 16: 1375-1380.
5. George A, William H, John E, et al. 2008. A within-group design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline. Alcohol Clin Exp Res 33: 315-323.
6. GoodmanW, Price L, Rasmussen S, Mazure C, Fleischman R, Hill C. 1989. The Yale-Brown Obsessive-compulsive Scale I: development, use, and reliability. Arch Gen Psychiatry 46: 1006.
7. Hasler W. 2009. Serotonin and the GI tract. Curr Gastroenterol Rep 11: 383-391.
8. Hewlett A, Sabine P, Salomon R. 2002. Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. J Clin Psychiatry 64: 1025-1030.
9. Holbrook D, Gill H, Zebda N, et al. 2009. Characterizationof 5-HT3C, 5-HT3D and 5-HT3E receptor subunits: evolution, distribution and function. J Neurochem 108: 384-396.
10. Hollander E, DeCaria C, Gully R, et al. 1991. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder. Psychiatry Res 36: 1-17.
11. Kaplan and Saddock. 2005. Comprehensive Handbook of Psychiatry, (8th edn) Lippincott Williams & Wilkins: Philadelphia; 2888-2914.
12. Karno M, Golding J, Sorenson Susan B, Burnam M. 1988. The epidemiolosiongy of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 45: 1094-1099.
13. Langston W, Joe E, Mark G, Lalit B. 2008. Effect of ondansetron on the incidence of vomiting associated with ketamine sedation in children: a double-blind, randomized, placebo-controlled trial. Ann Emerg Med 52: 30-34.
14. Larry F, Clark D. 2009. Ondansetron: an effective treatment for the withdrawal symptoms of opioids? Ther J 5: 637-640.
15. McDougle CJ, Fleischmann RL, Epperson CN, Wasylink S, Leckman JF, Price LH. 1995. Risperidone addition in fluvoxamine-refractory OCD: three cases. J Clin Psychiatry 56: 526-528.
16. McDougle J, Goodman K, Leckman F, et al. 1993. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 150: 647-649.
17. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. 1994. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind placebo-controlled study in-patients with or without tics. Arch Gen Psychiatry 51: 302-308.
18. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. 2009. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs 12: 1047-1055.
19. Pigott T, L'heureux F, Hill J, et al. 1992. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 12: 11-18.
20. Pigott A, Pato M, L'heureux F, et al. 1991. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with OCD. J Clin Psychopharmacol 11: 242-248.
21. Stern T, Jenike M. 1993. Treatment of obsessive-compulsive disorder with lithium carbonate. Psychosomatics 24: 673-674.
22. Tincello DG, Johnstone MJ. 1996. Treatment of hyperemesis gravidarum with the 5-HT3 antagonist ondansetron (Zofran). Postgrad Med J 72: 688-689.
23. Tonini M. 2005. 5-Hydroxytryptamine effect in the gut: the 3, 4 and 7 receptors. Neurogastroenterol Motil 17: 637-642.
24. Weissman M, Bland R, Canino G, Greenwald S. 1994. The cross-national epidemiology of obsessive-compulsive disorder. J Clin Psychiatry 55: 5-10.
25. Zohar J, Sasson Y. 1997. Obsessive-compulsive disorder: opportunities within and beyond the serotonergic domain. Acta Neuropsychiatr 9: 84-86.